Myeloma Patients Europe (MPE) and Amgen are launching a survey for European myeloma patients to understand their information needs.
If you are a myeloma patient living in the UK, who has received at least one prior treatment or are currently on your first treatment, MPE would be very grateful if you would take the time to complete the anonymous survey.
The survey will be run in 12 European countries, however, at this stage we need responses from UK patients only.
You can find the link to the survey here.
The survey has been developed in collaboration with the pharmaceutical company Amgen.
The survey asks patients a range of questions designed to better understand myeloma patient information needs and preferences, particularly focusing on the types of information that are valued by patients to make informed treatment decisions.
It also aims to understand:
- Patient involvement in their last treatment decision and the factors that influenced this
- How information is associated with confidence in treatment decision-making
- Communication between healthcare professionals and patients on treatment decisions
The results of the survey will provide valuable insight into the needs of patients and will be used to inform the information provision strategies of a wide range of stakeholders, including pharmaceutical companies and patient groups. MPE, and its members, will also utilise the results of the survey to inform their advocacy and campaigning strategies which aim to improve the experience of patients across Europe.
Alongside the UK, the survey is being currently being translated and will be run in 12 different European countries: Austria, Finland, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Sweden and Switzerland.
The study ultimately aims to enrol 1,000 myeloma patients across Europe. Running the survey in different countries will enable country specific and comparative analysis of the results, allowing for an understanding of the differences in patient experience in different parts of Europe.
Where can I find further information?
MPE and Amgen would like to thank-you in advance for completing the survey.